IGF-1 LR3 (1mg Vial)

01 · At a glance

Quickstart Highlights

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified analog of human IGF-1 with significantly extended half-life, studied for its anabolic and metabolic effects [1] . This synthetic variant exhibits reduced binding to IGF binding proteins, allowing enhanced bioavailability and systemic activity [2] . This educational protocol presents a once-daily subcutaneous approach with conservative titration for research applications.

02 · Dosing & reconstitution

Dosing & Reconstitution Guide

A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.

Standard / Gradual Approach (3 mL = ~0.333 mg/mL)

20–50 mcg once daily subcutaneously (gradual titration recommended).

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall to avoid foaming; do not shake.
3. Gently swirl or roll until the lyophilized powder dissolves completely into a clear solution.
4. Label the vial with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
5. Use within 30 days of reconstitution; for longer storage, prepare aliquots and freeze at −20 °C (−4 °F) for up to 3–6 months [4] .

03 · What you'll need

Supplies Needed

Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.

Protocol Overview

• Goal: Support anabolic processes and metabolic function through enhanced IGF-1 activity with extended bioavailability [1] .
• Schedule: Daily subcutaneous injections for 8 weeks (standard cycle); may extend to 12 weeks with appropriate off-periods.
• Dose Range: 20–50 mcg daily with gradual titration; conservative protocols remain at ≤50 mcg/day.
• Reconstitution: 3.0 mL per 1 mg vial (~0.333 mg/mL or 333 mcg/mL) for precise unit measurements.
• Storage: Lyophilized powder frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw cycles. Cycling: Common approach is 8 weeks on, 4–8 weeks off to prevent receptor desensitization [7] .

Dosing Protocol

• Suggested daily titration approach for tolerance assessment.
• Start (Weeks 1–2): 20 mcg daily to assess tolerance, particularly regarding blood glucose effects [6] .
• Titrate (Weeks 3–4): Increase to 40 mcg daily if Week 1–2 well-tolerated with no significant hypoglycemic symptoms.
• Maintain (Weeks 5–8): Hold at 50 mcg daily; this is considered the conservative upper end for most research protocols [2] .
• Frequency: Once per day subcutaneously; timing often aligned with meals (morning or post-workout) to manage insulin-like effects.
• Cycle Length: 8 weeks is standard; 12-week protocols exist but may show diminished returns beyond Week 6–8 [7] .
• Site Rotation: Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent local irritation or lipohypertrophy [8] .

Storage Instructions

• Lyophilized: freeze at −20 °C (−4 °F) for up to 12 months; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days; avoid repeated freeze–thaw cycles.
• Storage: Lyophilized powder frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw cycles. Cycling: Common approach is 8 weeks on, 4–8 weeks off to prevent receptor desensitization [7] .
• Keep mixed and unmixed items clearly labeled so inventory and dose logs stay accurate.

04 · Good to know

Important Notes

• Practical considerations for consistency, safety, and optimal outcomes.
• Sterile technique: Always use new, sterile insulin syringes for each injection; dispose immediately in a sharps container [5] .
• Follow “one needle, one syringe, only one time” practice.
• Site rotation: Systematically rotate injection sites between abdomen (at least 2 inches from navel), outer thighs, and upper arms to reduce local irritation and prevent tissue hardening [8] .
• Injection technique: Inject slowly and steadily; wait a few seconds before withdrawing the needle to prevent solution leakage.
• Hypoglycemia awareness: Be vigilant for signs of low blood sugar (shakiness, dizziness, sweating) especially during dose escalation; have fast-acting carbohydrates readily available [6] .
• Timing with meals: Administer with or shortly after food intake to mitigate insulin-like effects on blood glucose [3] .

05 · How it works

How This Works

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified analog of human IGF-1 with significantly extended half-life, studied for its anabolic and metabolic effects [1] .

This synthetic variant exhibits reduced binding to IGF binding proteins, allowing enhanced bioavailability and systemic activity [2] .

This educational protocol presents a once-daily subcutaneous approach with conservative titration for research applications.

The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.

06 · Daily habits

Lifestyle Factors

• Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
• Track body metrics only if they are relevant to the user's goal and approved data sources.
• Use consistent timing and logging habits so adherence data is meaningful.

07 · What to expect

Potential Benefits & Side Effects

• IGF-1 LR3 observations should be recorded conservatively: expected research endpoints, tolerability notes, injection-site reactions when applicable, sleep, appetite, energy, mood, and any adverse or unusual response.
• This section is not a claim of therapeutic benefit.

08 · Technique

Injection Technique

09 · Evidence

References